This research focuses on how certain drugs or their metabolites can form permanent (covalent) bonds with proteins, specifically at cysteine sites. These covalent interactions are a double-edged sword: on one hand, they can make drugs more powerful and long-lasting; on the other, they can trigger unwanted side effects if the wrong proteins are modified.
Traditionally, identifying cysteine-binding drugs has been slow and technically demanding, often relying on specialized probes or large-scale proteomics experiments. This study introduces a simpler and faster LC-MS/MS-based strategy that predicts and detects cysteine–drug conjugates using an in-house database and targeted mass spectrometry signals. In plain terms, it acts like a smart filter, scanning complex biological samples to find molecules that have actually “latched onto” cysteine residues.
A key novelty is that the method works well for drug repurposing. Instead of starting from scratch, researchers can re-examine existing drugs and their metabolites to see whether they form covalent protein bonds that might explain hidden therapeutic effects—or previously unexplained toxicity.
The potential impact is significant. This strategy helps researchers distinguish useful covalent interactions from harmful ones, improving drug safety while accelerating the discovery of next-generation covalent medicines. Ultimately, it supports smarter drug design by revealing how and where drugs truly interact with proteins inside living systems.
Reference
X. Hu, J.-L. Wu, Q. He, Z.-Q. Xiong, and N. Li, “Strategy for cysteine-targeting covalent inhibitors screening using in-house database-based LC-MS/MS and drug repurposing,” Journal of Pharmaceutical Analysis, vol. 15, article 101045, 2025, doi: 10.1016/j.jpha.2024.101045.
